Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Female Reproductive SystemDRG 744-d-c-conization-laparoscopy-and-tubal-interruption-with-cc-mcc
    Ask Trek AI about this page

    D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview

    DRG 744 includes inpatient admissions involving dilation and curettage, cervical conization, laparoscopy, and tubal interruption when a Major Complication or Comorbidity or Complication or Comorbidity is present, affecting resource intensity. This Diagnosis-Related Group is important for inpatient reimbursement because the presence of a Major Complication or Comorbidity or Complication or Comorbidity changes payment relative to less complex cases.

    Customize your policy alerts

    Sign up for drg 744 policy alerts

    Get alerted when payer policies referencing 744 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 744 Overview

    DRG 744 covers inpatient admissions for dilation and curettage, cervical conization, laparoscopy, and tubal interruption when a Major Complication or Comorbidity or Complication or Comorbidity is present. This Diagnosis-Related Group bundles related gynecologic procedural care and associated inpatient resources for Medicare beneficiaries. It matters for Medicare payment because presence of a Major Complication or Comorbidity or Complication or Comorbidity elevates relative resource use and reimbursement compared with cases without these diagnoses. Hospitals use the Diagnosis-Related Group assignment to determine base Medicare inpatient payments for these procedures.

    Table of contents

    Progress1 / 5

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    National Payment Rates

    Across commercial payers the observed rate range spans from about $370 up to $62K, with the widest spread between minimum and maximum seen in Anthem. Refer to the payer table and the accompanying chart below for payer-specific quartiles and distribution details. Payer labels shown include Blue Cross Blue Shield, Anthem, Cigna, and Aetna.

    The CMS 2023 data are national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 744 in 2023. Values reflect national-level averages and case volumes for Medicare FFS beneficiaries.

    Average Total PaymentAverage Submitted ChargesAverage Medicare PaymentTotal Discharges
    $19K$97K$16K1.1K

    Patient Population

    This DRG’s patient population is mixed but leans toward working-age adults rather than predominantly Medicare-age beneficiaries. Medicare discharges represent a portion of overall volume (1,116 total Medicare discharges in 2023), indicating both commercial and Medicare payers cover these admissions. Expect a mix of privately insured (working-age) and Medicare-age patients rather than a population exclusively Medicare-age.

    State Payment Rates

    State: Alaska1 / 49

    Alaska Benchmarks

    Payer rates in Alaska range from $32K to $82K, reflecting substantial dispersion across carriers. Cigna’s $82K maximum and $49K mean stand out as the most notable deviation above national averages, while Anthem and Blue Cross Blue Shield cluster at $32K on the low end. See the table and chart below for payer-level detail.

    Key Insights for Alaska

    • Cigna is the highest-paying payer in Alaska at $82K, while Anthem and BCBS both report the lowest observed rate at $32K.
    • Alaska’s mean of $49K (Cigna) sits notably above national medians for similar DRGs, indicating a meaningful upward deviation driven by Cigna’s rates.

    Clinical Trials

    • Trials comparing surgical techniques and intraoperative management for procedures such as dilation and curettage (D&C), cervical conization, diagnostic or operative laparoscopy, and tubal interruption. These studies enroll hospitalized reproductive-age and peri‑menopausal women undergoing these procedures for indications like abnormal uterine bleeding, cervical dysplasia, ectopic pregnancy evaluation, or sterilization, and evaluate outcomes such as operative time, blood loss, anesthesia approaches, conversion to open surgery, and perioperative complication rates. Results inform surgeons and hospitals about best practices to reduce length of stay, resource use, and complication-related costs that directly affect DRG-based reimbursements.
    • Comparative effectiveness studies of perioperative infection prevention, hemorrhage control, and thromboprophylaxis strategies in this mixed-surgery cohort. These pragmatic trials or registry analyses assess different antibiotic regimens, local hemostatic agents, uterotonic use, and VTE prophylaxis protocols in patients with varying comorbidities (eg, coagulopathy, obesity, diabetes) to measure rates of postoperative infection, reoperation, transfusion, and readmission. Findings are relevant to payers and providers because they target preventable complications and readmissions that drive CC/MCC assignment and higher reimbursement tiers, and can support standardized protocols to improve outcomes and lower avoidable costs.
    • Post-discharge outcomes and patient-reported outcomes research examining recovery trajectories, fertility and quality-of-life impacts, and long-term complications after these gynecologic procedures. Cohort studies and prospective observational research follow patients discharged under DRG 744 to quantify time to return to baseline function, incidence of chronic pelvic pain, subsequent fertility interventions, and health care utilization over 30–90 days. This area matters for discharge planning, post-acute care allocation, and payer assessments of downstream costs and value, helping health systems optimize care pathways and identify patients who may benefit from intensified follow-up to prevent costly late complications.

    Related Codes

    734-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITH-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC: Inpatient Reimbursement Overview

    735-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITHOUT-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy: Inpatient Reimbursement Overview

    736-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    737-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    738-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    739-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    740-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    741-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    742-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITH-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy with CC/MCC: Inpatient Reimbursement Overview

    743-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Mean Rates by Payer — National — DRG 744
    Mean Rates by Payer — Alaska — DRG 744